Crestwood Advisors Group LLC Grows Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Crestwood Advisors Group LLC boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 37.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,037 shares of the medical research company's stock after buying an additional 35,721 shares during the quarter. Crestwood Advisors Group LLC owned approximately 0.07% of IQVIA worth $23,102,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in IQV. Brighton Jones LLC grew its position in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after buying an additional 2,537 shares during the period. Commonwealth Equity Services LLC lifted its holdings in IQVIA by 0.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 26,104 shares of the medical research company's stock valued at $5,130,000 after purchasing an additional 157 shares in the last quarter. Intech Investment Management LLC lifted its holdings in IQVIA by 159.2% during the fourth quarter. Intech Investment Management LLC now owns 2,444 shares of the medical research company's stock valued at $480,000 after purchasing an additional 1,501 shares in the last quarter. Lee Danner & Bass Inc. purchased a new position in IQVIA during the fourth quarter valued at approximately $44,000. Finally, Millstone Evans Group LLC purchased a new position in IQVIA during the fourth quarter valued at approximately $198,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 4.1%

IQV stock traded up $7.94 during mid-day trading on Thursday, reaching $202.18. 2,889,235 shares of the stock traded hands, compared to its average volume of 2,023,230. The business has a 50-day moving average price of $154.75 and a two-hundred day moving average price of $170.52. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.82 and a current ratio of 0.84. The stock has a market capitalization of $34.98 billion, a PE ratio of 29.25, a PEG ratio of 2.21 and a beta of 1.30. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. The firm had revenue of $4.02 billion for the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.64 earnings per share. Equities research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

IQV has been the topic of several analyst reports. Evercore ISI lifted their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Robert W. Baird lifted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Barclays upped their target price on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Finally, William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday. Eight investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $227.64.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.